Cargando…

Enzyme-Enhanced Codelivery of Doxorubicin and Bcl-2 Inhibitor by Electrospun Nanofibers for Synergistic Inhibition of Prostate Cancer Recurrence

One of the great challenges of postoperative prostate cancer management is tumor recurrence. Although postoperative chemotherapy presents benefits to inhibit unexpected recurrence, it is still limited due to the drug resistance or intolerable complications of some patients. Electrospun nanofiber, as...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zheng, Luo, Xing, Mo, Yongxin, Zhao, Pengkai, Wang, Haixia, Fang, Youqiang, Xu, Yanteng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610395/
https://www.ncbi.nlm.nih.gov/pubmed/36297356
http://dx.doi.org/10.3390/ph15101244
_version_ 1784819259089616896
author Liu, Zheng
Luo, Xing
Mo, Yongxin
Zhao, Pengkai
Wang, Haixia
Fang, Youqiang
Xu, Yanteng
author_facet Liu, Zheng
Luo, Xing
Mo, Yongxin
Zhao, Pengkai
Wang, Haixia
Fang, Youqiang
Xu, Yanteng
author_sort Liu, Zheng
collection PubMed
description One of the great challenges of postoperative prostate cancer management is tumor recurrence. Although postoperative chemotherapy presents benefits to inhibit unexpected recurrence, it is still limited due to the drug resistance or intolerable complications of some patients. Electrospun nanofiber, as a promising drug carrier, demonstrating sustained drug release behavior, can be implanted into the tumor resection site during surgery and is conductive to tumor inhibition. Herein, we fabricated electrospun nanofibers loaded with doxorubicin (DOX) and ABT199 to synergistically prevent postoperative tumor recurrence. Enzymatic degradation of the biodegradable electrospun nanofibers facilitated the release of the two drugs. The primarily released DOX from the electrospun nanofibers effectively inhibited tumor recurrence. However, the sustained release of DOX led to drug resistance of the tumor cells, yielding unsatisfactory eradication of the residual tumor. Remarkably, the combined administration of DOX and ABT199, simultaneously released from the nanofibers, not only prolonged the chemotherapy by DOX but also overcame the drug resistance via inhibiting the Bcl-2 activation and thereby enhancing the apoptosis of tumor cells by ABT199. This dual-drug-loaded implant system, combining efficient chemotherapy and anti-drug resistance, offers a prospective strategy for the potent inhibition of postoperative tumor recurrence.
format Online
Article
Text
id pubmed-9610395
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96103952022-10-28 Enzyme-Enhanced Codelivery of Doxorubicin and Bcl-2 Inhibitor by Electrospun Nanofibers for Synergistic Inhibition of Prostate Cancer Recurrence Liu, Zheng Luo, Xing Mo, Yongxin Zhao, Pengkai Wang, Haixia Fang, Youqiang Xu, Yanteng Pharmaceuticals (Basel) Article One of the great challenges of postoperative prostate cancer management is tumor recurrence. Although postoperative chemotherapy presents benefits to inhibit unexpected recurrence, it is still limited due to the drug resistance or intolerable complications of some patients. Electrospun nanofiber, as a promising drug carrier, demonstrating sustained drug release behavior, can be implanted into the tumor resection site during surgery and is conductive to tumor inhibition. Herein, we fabricated electrospun nanofibers loaded with doxorubicin (DOX) and ABT199 to synergistically prevent postoperative tumor recurrence. Enzymatic degradation of the biodegradable electrospun nanofibers facilitated the release of the two drugs. The primarily released DOX from the electrospun nanofibers effectively inhibited tumor recurrence. However, the sustained release of DOX led to drug resistance of the tumor cells, yielding unsatisfactory eradication of the residual tumor. Remarkably, the combined administration of DOX and ABT199, simultaneously released from the nanofibers, not only prolonged the chemotherapy by DOX but also overcame the drug resistance via inhibiting the Bcl-2 activation and thereby enhancing the apoptosis of tumor cells by ABT199. This dual-drug-loaded implant system, combining efficient chemotherapy and anti-drug resistance, offers a prospective strategy for the potent inhibition of postoperative tumor recurrence. MDPI 2022-10-10 /pmc/articles/PMC9610395/ /pubmed/36297356 http://dx.doi.org/10.3390/ph15101244 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Liu, Zheng
Luo, Xing
Mo, Yongxin
Zhao, Pengkai
Wang, Haixia
Fang, Youqiang
Xu, Yanteng
Enzyme-Enhanced Codelivery of Doxorubicin and Bcl-2 Inhibitor by Electrospun Nanofibers for Synergistic Inhibition of Prostate Cancer Recurrence
title Enzyme-Enhanced Codelivery of Doxorubicin and Bcl-2 Inhibitor by Electrospun Nanofibers for Synergistic Inhibition of Prostate Cancer Recurrence
title_full Enzyme-Enhanced Codelivery of Doxorubicin and Bcl-2 Inhibitor by Electrospun Nanofibers for Synergistic Inhibition of Prostate Cancer Recurrence
title_fullStr Enzyme-Enhanced Codelivery of Doxorubicin and Bcl-2 Inhibitor by Electrospun Nanofibers for Synergistic Inhibition of Prostate Cancer Recurrence
title_full_unstemmed Enzyme-Enhanced Codelivery of Doxorubicin and Bcl-2 Inhibitor by Electrospun Nanofibers for Synergistic Inhibition of Prostate Cancer Recurrence
title_short Enzyme-Enhanced Codelivery of Doxorubicin and Bcl-2 Inhibitor by Electrospun Nanofibers for Synergistic Inhibition of Prostate Cancer Recurrence
title_sort enzyme-enhanced codelivery of doxorubicin and bcl-2 inhibitor by electrospun nanofibers for synergistic inhibition of prostate cancer recurrence
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610395/
https://www.ncbi.nlm.nih.gov/pubmed/36297356
http://dx.doi.org/10.3390/ph15101244
work_keys_str_mv AT liuzheng enzymeenhancedcodeliveryofdoxorubicinandbcl2inhibitorbyelectrospunnanofibersforsynergisticinhibitionofprostatecancerrecurrence
AT luoxing enzymeenhancedcodeliveryofdoxorubicinandbcl2inhibitorbyelectrospunnanofibersforsynergisticinhibitionofprostatecancerrecurrence
AT moyongxin enzymeenhancedcodeliveryofdoxorubicinandbcl2inhibitorbyelectrospunnanofibersforsynergisticinhibitionofprostatecancerrecurrence
AT zhaopengkai enzymeenhancedcodeliveryofdoxorubicinandbcl2inhibitorbyelectrospunnanofibersforsynergisticinhibitionofprostatecancerrecurrence
AT wanghaixia enzymeenhancedcodeliveryofdoxorubicinandbcl2inhibitorbyelectrospunnanofibersforsynergisticinhibitionofprostatecancerrecurrence
AT fangyouqiang enzymeenhancedcodeliveryofdoxorubicinandbcl2inhibitorbyelectrospunnanofibersforsynergisticinhibitionofprostatecancerrecurrence
AT xuyanteng enzymeenhancedcodeliveryofdoxorubicinandbcl2inhibitorbyelectrospunnanofibersforsynergisticinhibitionofprostatecancerrecurrence